Aveanna Healthcare (NASDAQ:AVAH) Issues Quarterly Earnings Results

Key Points

• Aveanna Healthcare beat second-quarter expectations: EPS was $0.22 versus the $0.17 consensus, while revenue rose 13.7% year over year to $670.5 million, above estimates of $638.6 million. Adjusted EBITDA increased 8% to $95.4 million.
• Management raised 2026 guidance to revenue above $2.68 billion and adjusted EBITDA above $365 million, citing continued organic growth across its operating segments and improved reimbursement conditions.
• Key risks remain: reimbursement gains are expected to flow largely through to caregiver wages, potentially limiting margin expansion, while the company carries approximately $1.48 billion in variable-rate debt and remains highly leveraged.

Aveanna Healthcare (NASDAQ:AVAH - Get Free Report) released its quarterly earnings results on Thursday. The company reported $0.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.17 by $0.05, FiscalAI reports. The firm had revenue of $670.48 million during the quarter, compared to analyst estimates of $638.61 million. Aveanna Healthcare had a net margin of 10.37% and a return on equity of 124.68%.

Here are the key takeaways from Aveanna Healthcare's conference call:

• Q2 revenue rose 13.7% to $670.5 million, while adjusted EBITDA increased 8% to $95.4 million, with year-over-year growth across all three operating segments.
• Aveanna raised 2026 guidance to revenue above $2.68 billion and adjusted EBITDA above $365 million, attributing the increase to core organic performance rather than the recently acquired Family First business.
• The company reported progress on reimbursement and payer initiatives, including seven state rate increases, 37 Private Duty Services preferred payer agreements, and a significant California pediatric nursing rate increase scheduled for January 2027. Aveanna also lifted its long-term organic growth targets for Private Duty Services to 5%–6% and Home Health and Hospice to 8%–10%.
• Management expects gross-margin percentages to remain broadly stable because reimbursement gains will largely be passed through to caregiver wages; it plans to raise California wages ahead of the January 2027 rate increase, creating potential near-term margin pressure. The company also remains highly leveraged, with approximately $1.48 billion of variable-rate debt, despite targeting leverage below 3x over time.

Aveanna Healthcare Stock Performance

Shares of NASDAQ AVAH traded up $1.50 during midday trading on Thursday, reaching $10.55. The company's stock had a trading volume of 4,582,757 shares, compared to its average volume of 1,613,173. The stock has a market capitalization of $2.30 billion, a P/E ratio of 8.93, a PEG ratio of 0.89 and a beta of 1.90. The company has a debt-to-equity ratio of 5.35, a current ratio of 1.47 and a quick ratio of 1.47. The firm has a 50 day moving average price of $8.77 and a 200-day moving average price of $7.71. Aveanna Healthcare has a 12-month low of $5.93 and a 12-month high of $10.91.

Trending Headlines about Aveanna Healthcare

Here are the key news stories impacting Aveanna Healthcare this week:

• Positive Sentiment: Q2 results exceeded expectations. Aveanna reported adjusted earnings of $0.22 per share, above the $0.17 analyst consensus and up from $0.18 a year earlier. Revenue rose 13.7% year over year to $670.5 million, surpassing estimates of approximately $638.6 million. Aveanna Healthcare Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: Profitability improved materially. Second-quarter net income increased to $40.3 million from $27.0 million in the prior-year period, while adjusted EBITDA grew 8.0% to $95.4 million. The company reported a 10.37% net margin and 124.68% return on equity. Aveanna Healthcare Announces Second Quarter Financial Results and Revised 2026 Guidance
• Positive Sentiment: Full-year guidance was raised. Aveanna increased 2026 revenue guidance to more than $2.68 billion, from $2.63 billion to $2.65 billion previously. Adjusted EBITDA guidance was raised to above $365 million, versus the prior range of $338 million to $342 million. The upgrades suggest management sees continued momentum in its home-care operations. Aveanna Healthcare Revised 2026 Guidance
• Neutral Sentiment: Separate coverage is examining the quarter’s operating metrics against Wall Street estimates and year-ago results. The company’s FY 2026 EPS guidance entry did not provide a usable figure, limiting the earnings outlook to revenue and adjusted EBITDA. Aveanna Q2 Earnings Key Metrics
• Neutral Sentiment: Reported short interest was listed at zero shares, offering no meaningful indication of bearish positioning or potential short-covering demand.

Insider Activity at Aveanna Healthcare

In related news, insider Patrick A. Cunningham sold 125,000 shares of the business's stock in a transaction that occurred on Wednesday, May 20th. The shares were sold at an average price of $7.59, for a total transaction of $948,750.00. Following the completion of the transaction, the insider owned 212,755 shares of the company's stock, valued at approximately $1,614,810.45. The trade was a 37.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder J.H. Whitney Equity Partners V sold 5,842,240 shares of the company's stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $6.24, for a total transaction of $36,455,577.60. Following the completion of the transaction, the insider owned 13,450,547 shares in the company, valued at approximately $83,931,413.28. This trade represents a 30.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 31,305,664 shares of company stock worth $215,555,910 in the last ninety days. Corporate insiders own 5.30% of the company's stock.

Institutional Investors Weigh In On Aveanna Healthcare

Several hedge funds have recently added to or reduced their stakes in the company. Invesco Ltd. lifted its position in Aveanna Healthcare by 1,001.5% in the 4th quarter. Invesco Ltd. now owns 360,464 shares of the company's stock worth $2,945,000 after buying an additional 327,738 shares during the last quarter. Mackenzie Financial Corp grew its holdings in Aveanna Healthcare by 12.7% in the 4th quarter. Mackenzie Financial Corp now owns 216,200 shares of the company's stock worth $1,810,000 after acquiring an additional 24,447 shares during the last quarter. Zimmer Partners LP purchased a new position in Aveanna Healthcare during the 4th quarter valued at about $6,189,000. Voloridge Investment Management LLC bought a new position in shares of Aveanna Healthcare during the fourth quarter valued at approximately $1,915,000. Finally, Millennium Management LLC lifted its position in shares of Aveanna Healthcare by 1,007.1% in the 4th quarter. Millennium Management LLC now owns 1,114,717 shares of the company's stock worth $9,107,000 after purchasing an additional 1,014,030 shares during the period. Institutional investors own 87.96% of the company's stock.

Wall Street Analyst Weigh In

AVAH has been the topic of several recent analyst reports. Royal Bank Of Canada upgraded shares of Aveanna Healthcare from a "sector perform" rating to an "outperform" rating and set a $10.00 target price on the stock in a report on Wednesday, June 3rd. Weiss Ratings reaffirmed a "hold (c+)" rating on shares of Aveanna Healthcare in a research note on Thursday, July 2nd. Barclays increased their target price on shares of Aveanna Healthcare from $9.00 to $9.50 and gave the stock an "overweight" rating in a research note on Thursday, July 9th. Truist Financial lifted their price target on shares of Aveanna Healthcare from $9.00 to $11.00 and gave the company a "hold" rating in a research note on Tuesday, July 14th. Finally, Stephens raised Aveanna Healthcare from an "equal weight" rating to an "overweight" rating and upped their price target for the stock from $10.00 to $11.00 in a research note on Friday, May 15th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $10.78.

About Aveanna Healthcare

Aveanna Healthcare, Inc NASDAQ: AVAH is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna's offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source